Clinical Trials Logo

Multiple Myeloma, Refractory clinical trials

View clinical trials related to Multiple Myeloma, Refractory.

Filter by:

NCT ID: NCT06411301 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

AcTRESS
Start date: October 2024
Phase: Phase 1
Study type: Interventional

This study aims to determine the safety and the recommended phase II dose of RYZ101 (actinium-225 labelled DOTA-octreotate (225Ac-DOTATATE)) in participants with refractory and relapsing multiple myeloma (MM) that have received at least 3 prior lines of myeloma therapy. Participants will be selected based on somatostatin receptor (SSTR) positivity assessed by gallium-68 labelled DOTA-octreotate (68Ga-DOTATATE) PET/CT. The response to 225Ac-DOTATATE therapy will also be assessed in the target study population.

NCT ID: NCT06242249 Not yet recruiting - Clinical trials for Multiple Myeloma, Refractory

Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

Start date: April 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including BCMA, with CAR-NK cells in multiple myeloma. To further investigate the potential of BCMA-targeted CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard therapy.

NCT ID: NCT06225310 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

KPT-IST-391
Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

NCT ID: NCT06158412 Recruiting - Clinical trials for Multiple Myeloma in Relapse

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Start date: November 22, 2023
Phase: Phase 2
Study type: Interventional

To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma.

NCT ID: NCT06115135 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

NCT ID: NCT06012383 Completed - Clinical trials for Multiple Myeloma, Refractory

Alvocade® (Bortezomib) Safety and Effectiveness Study

Start date: July 2016
Phase:
Study type: Observational

This study is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Alvocade® use in Iranian patients with multiple myeloma. No control groups were considered in the study design. The primary objective of this study was safety assessment, including the incidence of adverse events (AEs).

NCT ID: NCT05909826 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

KMM-KCd
Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.

NCT ID: NCT05836896 Recruiting - Neoplasms Clinical Trials

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

CARLOTTA01
Start date: February 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies

NCT ID: NCT05749133 Recruiting - Clinical trials for Multiple Myeloma in Relapse

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Start date: April 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

It is a single-center, open-labeled, single-arm, non-randomized investigatorinitiated trial evaluating the efficacy and safety of anti-GPRC5D CAR-T cells therapy for relapsed and refractory(r/r) multiple myeloma(MM) after three or more lines of treatments.

NCT ID: NCT05747586 Recruiting - Clinical trials for Multiple Myeloma in Relapse

BCMA CAR-NK For Patients With RRMM

Start date: February 2023
Phase: N/A
Study type: Interventional

This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of BCMA CAR-NK cells in the treatment of relapsed or/and refractory MM. The primary endpoints are dose limiting toxicity (DLT) and Maximal tolerability evaluation (MTD).